Ongoing Disclosure Notice - A Urlwin
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Infratil Limited (IFT)
Date this disclosure made:
2-Dec-24
Date of last disclosure:
19-Jul-24
Director or senior manager giving disclosure
Full name(s):
Anne June Urlwin
Name of listed issuer:
Infratil Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares in IFT
Nature of the affected relevant interest(s):
Relevant interest arises as:
* Anne is a director, and person who has the
power to (among other things) exercise, or
control the exercise of, the right to vote
attached to 20% or more of the voting
products, of Clifton Creek Limited (1151619).
* Clifton Creek Limited is the sole registered
holder and beneficial owner of the relevant IFT
financial products.
For that relevant interest-
Number held in class before acquisition or disposal:
20,829
Number held in class after acquisition or disposal:
24,829
Current registered holder(s):
N/A
Registered holder(s) once transfers are registered:
Clifton Creek Limited
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
1
Details of transactions requiring disclosure-
Date of transaction:27-Nov-24
Nature of transaction: Acquisition of shares on-market
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:$50,745.20 ($12.69 per share)
Number of financial products to which the transaction related: 4,000
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:N/A
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
IFT340 15/03/2031 7.08%
Infrastructure Bonds in IFT
Nature of relevant interest:
Relevant interest arises as:
* Anne is a director, and person who has the
power to (among other things) exercise, or
control the exercise of, the right to vote
attached to 20% or more of the voting
products, of Clifton Creek Limited (1151619).
* Clifton Creek Limited is the sole registered
holder and beneficial owner of the relevant IFT
financial products.
For that relevant interest,-
Number held in class:57,000
Current registered holder(s):Clifton Creek Limited
Class of quoted financial products:
IFT330 31/07/2029 6.9%
Infrastructure Bonds in IFT
Nature of relevant interest:
Relevant interest arises as:
* Anne is a director, and person who has the
power to (among other things) exercise, or
c
ontrol the exercise of, the right to vote
attached to 20% or more of the voting
products, of Clifton Creek Limited (1151619).
* Clifton Creek Limited is the sole registered
holder and beneficial owner of the relevant IFT
financial products.
For that relevant interest,-
Number held in class:56,000
C
urrent registered holder(s):
Clifton Creek Limited
Class of quoted financial products:
IFT350 17/12/2031 7.06%
Infrastructure Bonds in IFT
Nature of relevant interest:
Relevant interest arises as:
* Anne is a director, and person who has the
power to (among other things) exercise, or
c
ontrol the exercise of, the right to vote
attached to 20% or more of the voting
products, of Clifton Creek Limited (1151619).
* Clifton Creek Limited is the sole registered
holder and beneficial owner of the relevant IFT
financial products.
For that relevant interest,-
Number held in class:50,000
C
urrent registered holder(s):
Clifton Creek Limited
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of person authorised to sign on behalf of director or officer:
D
ate of signature:
2-Dec-24
Name and title of authorised person:Brendan Kevany, Company Secretary
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- IPL — Investore Property Limited: D&O Ongoing Disclosure2024-12-16
“Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(1) and 298(1), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Investore Property Limited Date this disclosure made: 16-Dec-24 Date of last discl…”
- AFT — AFT Pharmaceuticals Limited: Disclosure of Directors and Senior Managers Relevant Intere2024-12-02
“Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: AFT Pharmaceuticals Limited Date this disclosure made: 2-Dec-24 Date of last discl…”
- AFT — AFT Pharmaceuticals Limited: Disclosure of Directors and Senior Managers Relevant Int2024-11-27
“Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: AFT Pharmaceuticals Limited Date this disclosure made: 27-Nov-24 Date of last disc…”